Commentary

Video

Gene and Cell Therapy: Shaping the Future of Medicine

Author(s):

Marco Davila, MD, PhD

Marco Davila, MD, PhD, discusses how to shape the future of medicine with gene and cell therapy.

Marco Davila, MD, PhD, discusses how to shape the future of medicine with gene and cell therapy.

Related Videos
Andrew Ip, MD
Eunice S. Wang, MD
Marcella Ali Kaddoura, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.
Cedric Pobel, MD
Minoo Battiwalla, MD, MS
Related Content
FDA
December 20th 2024

FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
October 30th 2024

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

Ide-cel in multiple myeloma
December 10th 2024

Ide-Cel Shows Real-World Efficacy in CNS Multiple Myeloma

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
October 10th 2022

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Cilta-Cel Improves MRD-Negativity Rates in Lenalidomide-Refractory Myeloma
December 10th 2024

Cilta-Cel Improves MRD-Negativity Rates in Lenalidomide-Refractory Myeloma

Follicular Lymphoma
December 9th 2024

Tisagenlecleucel Maintains Long-Term Efficacy in R/R Follicular Lymphoma